In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

The Delaware Supreme Court rejected the legitimacy of expert testimony linking the heartburn drug Zantac to cancer, in a ...

Delaware's Supreme Court sides with drugmakers including GSK (GSK) and Pfizer (PFE), rejecting expert testimony linking ...

Delaware's highest court ruled on Thursday that nearly 75,000 patients suing four large drugmakers cannot introduce reports ...

Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal ...

A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making ...

Zantac became the world’s best-selling medicine in 1988 and one of the first to top US$1 billion in annual sales. (Getty Images/AFP pic) CHICAGO: ...

GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Sanofi will pay $100 million—or approximately $25,000 each—to roughly 4,000 claimants who filed Zantac lawsuits, according to a report from Bloomberg.

Zantac, an over-the-counter heartburn medicine in the US since 2004, was one of the world's best-selling drugs with tens of millions of regular and occasional users globally.

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...